


CLINICAL IMMUNOBIOLOGY

EDITED BY

Fritz H. Bach
Robert A. Good



Volume 2

ACADEMIC PRESS, INC. A Subsidiary of Harcourt Brace Jovanovich, Publishers

Clinical Immunobiology

Edited by

VOLUME 2

FRITZ H. BACH, M.D.

IMMUNOBIOLOGY RESEARCH CENTER
DEPARTMENTS OF MEDICAL GENETICS
AND SURGERY
UNIVERSITY OF WISCONSIN
MEDICAL SCHOOL
MADISON, WISCONSIN

ROBERT A. GOOD, Ph.D., M.D.

MEMORIAL SLOAN-KETTERING
CANCER CENTER
NEW YORK, NEW YORK



ACADEMIC PRESS New York and London 1974
A Subsidiary of Harcourt Brace Jovanovich, Publishers

COPYRIGHT © 1974, BY ACADEMIC PRESS, INC.

ALL RIGHTS RESERVED.

NO PART OF THIS PUBLICATION MAY BE REPRODUCED OR
TRANSMITTED IN ANY FORM OR BY ANY MEANS, ELECTRONIC
OR MECHANICAL, INCLUDING PHOTOCOPY, RECORDING, OR ANY
INFORMATION STORAGE AND RETRIEVAL SYSTEM, WITHOUT
PERMISSION IN WRITING FROM THE PUBLISHER.

ACADEMIC PRESS, INC.

111 Fifth Avenue, New York, New York 10003

United Kingdom Edition published by
ACADEMIC PRESS, INC. (LONDON) LTD.
24/28 Oval Road, London NW1

LIBRARY OF CONGRESS CATALOG CARD NUMBER: 72-77356

PRINTED IN THE UNITED STATES OF AMERICA

List of Contributors

Numbers in parentheses indicate the pages on which the authors' contributions begin.

- FRITZ, H. BACH, Immunobiology Research Center, Departments of Medical Genetics and Surgery, University of Wisconsin Medical School, Madison, Wisconsin (63)
- MORTIMER M. BORTIN, May and Sigmund Winter Research Laboratory, Mount Sinai Medical Center, and the Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin (287)
- I. FLORENTIN, Institut de Cancérologie et d'Immunogénétique, Hôpital Paul-Brousse, Villejuif, France (33)
- H. HUGH FUDENBERG, Department of Medicine, University of California, San Francisco, School of Medicine, San Francisco, California (153)
- E. GARCIA-GIRALT, Institut de Cancérologie et d'Immunogénétique, Hôpital Paul-Brousse, Villejuif, France (33)
- ROBERT A. GOOD, Memorial Sloan-Kettering Cancer Center, New York, New York (63)
- C. GRISCELLI, Immunology and Hematology Unit, Children's Medical Clinic, Hôpital des Enfants Malades, Paris, France (177)
- O. HALLE-PANNENKO, Institut de Cancérologie et d'Immunogénétique, Hôpital Paul-Brousse, Villejuif, France (33)

- INGEGERD HELLSTRÖM, Departments of Pathology and Microbiology, University of Washington School of Medicine, Seattle, Washington (233)
- KARL ERIK HELLSTRÖM, Departments of Pathology and Microbiology, University of Washington School of Medicine, Seattle, Washington (233)
- N. KIGER, Institut de Cancérologie et d'Immunogénétique, Hôpital Paul-Brousse, Villejuif, France (33)
- H. SHERWOOD LAWRENCE, Infectious Diseases and Immunology Division, Department of Medicine, New York University School of Medicine, New York, New York (115)
- ALAN S. LEVIN, Department of Dermatology, University of California, San Francisco, School of Medicine, San Francisco, California, and Kaiser-Permanente Hospital, San Francisco, California (153)
- G. MATHÉ, Institut de Cancérologie et d'Immunogénétique, Hôpital Paul-Brousse, Villejuif, France (33)
- HERBERT F. OETTGEN, Memorial Sloan-Kettering Cancer Center, New York, New York (205)
- RICHMOND T. PREHN, The Institute for Cancer Research, Fox Chase Center for Cancer and Medical Sciences, Philadelphia, Pennsylvania (191)
- JON R. SCHMIDTKE, Department of Surgery, University of Minnesota Health Sciences Center, Minneapolis, Minnesota (265)
- L. SCHWARZENBERG, Institut de Cancérologie et d'Immunogénétique, Hôpital Paul-Brousse, Villejuif, France (33)
- RICHARD L. SIMMONS, Department of Surgery, University of Minnesota Health Sciences Center, Minneapolis, Minnesota (265)
- LYNN E. SPITLER, Department of Medicine, University of California, San Francisco, School of Medicine, San Francisco, California, and Cancer Research Institute, Department of Medicine, University of California, San Francisco, San Francisco, California (153)
- E. DONNALL THOMAS, Department of Medicine, University of Washington School of Medicine, Seattle, Washington, and the United States Public Health Service Hospital, Seattle, Washington (1)

Preface

We present the second volume of the serial publication *Clinical Immunobiology*, which has been designed to help the physician and student keep abreast of advances in the burgeoning field of clinical immunobiology. In the initial volume we made an effort to give some background of the fundamental lore of this rapidly developing discipline. We now launch our considerations of the advances in clinical immunobiology by presenting through the writings of several leaders in the field progress being made to apply bone marrow transplantation to the treatment of such devastating diseases as aplastic anemia, aregenerative pancytopenia, leukemia, uniformly fatal severe combined immunodeficiency diseases, and Wiskott-Aldrich syndrome. The successes we report here represent, we are certain, only the toddling first steps in a new era of medical therapy. We will look to cellular engineering in the form of bone marrow and thymus transplantation, and ultimately to macromolecular pharmacology, to correct inborn errors of metabolism, the effects of exposure to excessive amounts of radiation or cytotoxic chemicals, and hematopoietic failure based on malfunction of the complex process of normal hematological development and maintenance.

In these articles it is clearly brought forward that studies of marrow transplantation in man have provided new and exciting leads to the understanding of fundamental biological principles. For example, these studies have generated vital efforts toward the wider application of our new understanding of the histocompatibility determinants in man. This will surely need to be expanded and developed in future issues because studies in this direction not only make possible better matching for marrow transplants heretofore thought to be impossible, but yield evidence of fundamental relationships between the histocompatibility

determinants and the capacity to maintain our individuality in a hostile world through the ability to recognize and eliminate from the body that which is not self. Further, fundamental new information about leukemia seems to be contained in the evidence that, after successful marrow transplantation for this disease, the transplanted marrow may catch the leukemia.

In the chapters by Lawrence, and Spittler, Levin, and Fudenberg, the rapidly expanding use of transfer factor to treat human disease is presented against its appropriate background of fundamental studies. With this approach, some of the most recalcitrant and devastating of man's diseases are now being treated with a methodology that apparently engages the immunological system—or refurbishes a flagging or depressed cellular immunity. The results in some instances have been so extraordinary and the diseases apparently manipulated favorably so awful that the objections to the theoretical validity of the transfer factor approach often stated by critics (for example, the editors) must be satisfied while progress in this fantastic form of macromolecular pharmacology is recorded. Because of its theoretical importance in the contexts of these contributions, a brief scientific report by Griscelli is presented—even though at the outset the editors promised no detailed scientific research papers in a series designed to present scientific advances to the practitioner and student in a digested form. In the work of Griscelli and his colleagues (that is, incidentally, supported by simultaneous discoveries by Ballou and others in Minneapolis), the possibility of reconciling the influence of transfer factor and the immunologic dogma may emerge; it looks as though transfer factor may not be acting as specifically as was originally thought. It is certainly much less difficult to harmonize a nonspecific influence of this relatively small molecule with the demands of molecular biology, than it is to postulate highly specific influence requiring the transfer of information. Perhaps inclusion of this bit of relatively raw research data is not such a bad idea, and from time to time the editors may use this approach as future controversies need to be resolved or an important advance documented before the dust has settled.

Because immunobiology is making a vigorous effort to analyze cancer and even to address the issue of prevention and treatment of cancer, as was indicated in George Klein's chapter in Volume 1, a major section of Volume 2—five chapters—is devoted to these struggles. Strong, very cogent criticisms of the theory of immunosurveillance against cancer as stated originally by Ehrlich, reiterated by Thomas in relation to transplantation immunity in 1958, and extensively promulgated by Burnet, Good, and others, presents a needed balance as the Hellströms, Schmidtke and Simmons, and Oettgen, and Bortin present different,

and apparently useful, ways not only for looking at, but for manipulating immunity to cancer. Prehn's concept that a little immunity may be essential to stimulate some malignant cells represents a fresh new view for which considerable support has been accumulated by the author and his associates. There seems little doubt that the general concept of immunosurveillance may have to be set aside or modified to fit those challenges.

In the chapter by the Hellströms, the importance of factors capable of suppressing the cellular immunity that regularly develops in experimental and clinical malignancies is described and defined. Antigen-antibody complexes appear to be among inhibiting factors which suggest a number of approaches to the abrogation of such an influence. Oettgen's chapter balances the Hellström view with evidence that states clearly the complexity of approaching cancer from the immunologic view. He emphasizes the fact that antibodies of appropriate class and nature may have usefulness as we approach cancer therapy and management with immunological tools. Indeed, evidence has accumulated that some of the cell-mediated immunities involved in resistance to cancer cells may utilize antibodies. Details of this advance will be set forward in a future volume. It is clear already that antibodies are not all bad in cancer, nor is cell-mediated immunity necessarily all good.

As was set down in the first volume by Starzl and Putnam, and Klein, it is clear that widely disseminated epithelial malignancy inadvertently transplanted along with successful organ transplants can be eliminated from the body by immunological attack if only the host can look at the tumor as though the antigens added are "strong" rather than "weak" antigens. The final two chapters in this series concern themselves with the possibilities of this approach. Simmons shows that in some experimental tumor systems manipulation of the surface of the cancer cell by enzymatic means can provide this advantage and will permit, in these experimental circumstances, prevention and even treatment of established cancer. Bortin presents ingenious means by which allogeneic recognition and immune assault might be used in approaching residual cancer or leukemia.

We anticipate that clinicians will find as much that is useful and exciting in the second compilation of this series as we have found in bringing together this cluster of advances in clinical immunobiology. It is becoming clear to us in responses to, and reflections on, Volumes 1 and 2, what some of the requirements of future volumes may be. Rapidly developing methodologies in this field require forthwith a volume defining the best and most useful immunobiologic methodologies presented in a manner that will be helpful to the physician and to his laboratory associates. This will come soon. The magnificent potential

of cellular engineering, coupled as it is to advancing knowledge of immunogenetics, requires that the current state of the latter part be put forward succinctly and clearly so that it can be understood and used by doctors. Rapidly developing knowledge of immunobiological perturbations during infection, and especially the clinical immunobiology of viral, bacterial, and fungal diseases and their relationships to autoimmunity, needs exposition. Descriptions of new knowledge of the primary immunodeficiencies, and especially of the diseases associated with genetically based perturbations of the biologic amplification systems, like complement and phagocytosis, must be attended to. Even the correction of some of these can be the basis for exciting reading. We feel certain that the series on advances in clinical immunobiology is fairly launched and we look forward to future volumes with enthusiasm.

Fritz H. BACH
ROBERT A. GOOD

Contents of Volume 1

Structure-Function Relations in the Lymphoid System

Robert A. Good

The Immunoglobulins

Richard Hong

Cellular Immunity

H. Sherwood Lawrence

Transplantation Immunology

Thomas E. Starzl and Charles W. Putnam

Immunological Tolerance

A. C. Allison

Inflammation

Michael T. Lamm and Chandler A. Stetson, Jr.

Fundamental Immunogenetics—Their Application
to Histocompatibility

Fritz H. Bach and Marilyn L. Bach

Humoral Amplification Systems in Inflammation

Lawrence G. Hunsicker, Bruce U. Wintroub, and

K. Frank Austen

Immunosuppression

Eugene M. Lance

Tumor Immunology

George Klein

Allergy

L. M. Lichtenstein

Immunological Deficiency Disease

Fred S. Rosen

Subject Index

Contents

List of Contributors	xi
Preface	xiii
Contents of Volume 1	xvii

Bone Marrow Transplantation

E. Donnell Thomas

I. Introduction	2
II. Terminology	4
III. Technique	4
IV. Histocompatibility	5
V. Preparation of the Recipient	7
VI. Clinical Results	8
VII. Special Consideration According to Underlying Disease	11
VIII. Support for the Patient without Marrow Function	16
IX. Success or Failure of Engraftment	21
X. GVH Disease	21
XI. Immunological Status of Long-Term Survivors of Marrow Transplantation	24
XII. Infection following Engraftment	25
XIII. Nature of Tolerance	26
XIV. Antileukemic Effect (Adoptive Immunotherapy)	27
XV. Malignant Transformation of Donor Cells	28
XVI. A Look at the Future	29
References	30

Bone Marrow Transplantation for Aplasias and Leukemias

*G. Mathé, L. Schwarzenberg, N. Kiger, I. Florentin,
O. Halle-Pannenko, and E. Garcia-Giralt*

I. The First Bone Marrow Grafts in Man after Irradiation Exposure	33
II. Experimental and Clinical Bone Marrow Graft in Leukemia after Irradiation Conditioning (GVH versus GVL)	34
III. Bone Marrow Graft in Aplasias and Leukemias after ALG Conditioning; Split Lymphocyte Chimerism	45
IV. Bone Marrow Transplantation Using a Combination of ALG and Cyclophosphamide	50
V. Experimental Research for New Means to Control GVH	52
References	60

Bone Marrow and Thymus Transplants: Cellular Engineering to Correct Primary Immunodeficiency

Robert A. Good and Fritz H. Bach

I. Lymphoid System Development and the Concept of Two Interacting Immunity Systems	65
II. Correction of the DiGeorge Syndrome by Thymus Transplantation	71
III. Bone Marrow Transplants to Correct Immunodeficiency Diseases	77
IV. Bone Marrow Transplant to Correct SCID	79
V. Bone Marrow Transplant in Treating the Wiskott-Aldrich (WA) Syndrome	81
VI. Aspiration as a Problem in SCID Patients Fully Reconstituted Immunologically by Bone Marrow Transplantation	86
VII. Efforts to Use Isolated Stem Cells from Immunological Reconstitution in SCID	87
VIII. Efforts to Use Bone Marrow Transplantation to Correct SCID When a Matched Sibling Donor Is Not Available	88
IX. Genetic Determination of Histocompatibility Characteristics in Men and Mice	92
X. Bone Marrow Transplantation to Correct SCID with a Donor Mismatched with Recipient at All HL-A SD Determinants but Matched at the LD Locus Controlling MLC	95
XI. Correction of Clq Deficiency by Marrow Transplantation in SCID	96
XII. Relationship of Successful Marrow Transplantation in Aregenerative Anemia and Leukemia to Transplantations used in SCID	97
XI. Correction of Clq Deficiency by Marrow Transplantation in SCID	96
XIII. Correction of SCID by Fetal Liver Transplantation	98
XIV. New Experimental Observations Relevant to Cellular Engineering in Man	100
XV. Cellular Engineering and Common Diseases of Man	102
XVI. Cellular Engineering and Immunodeficiencies Based on Defective Development of Biological Amplification Systems	103

XVII. Immunodeficiencies in Common Human Diseases—A Challenge for Cellular Engineering	105
XVIII. Nutritional Deprivation and Immunological Deficiency—A Possible Challenge for Cellular or Molecular Engineering	107
XIX. Aging and Cellular Engineering	107
Bibliography	108

Selective Immunotherapy with Transfer Factor

H. Sherwood Lawrence

I. Introduction	116
II. Early Beginnings—Viable Cells as Vehicles of TF	117
III. Histoincompatible Cell Transfer and Graft-versus-Host (GvH) Disease	119
IV. Viable Lymphocytes versus TF_D for Immunotherapy	120
V. Later Developments—Availability of TF_D	121
VI. The Scope of TF_D for Immunological Reconstitution	122
VII. TF_D Immunotherapy of Infectious Disease	124
VIII. Reconstitution of Congenital Immunodeficiency Diseases with TF_D Therapy	130
IX. TF_D and Cancer Immunotherapy	135
X. Immunotherapy with TF_D —Unresolved Questions	141
XI. Conclusion	149
References	150

Transfer Factor

Lynn E. Spitler, Alan S. Levin, and H. Hugh Fudenberg

I. Introduction	154
II. Preparation of Transfer Factor	155
III. Evaluation of Cellular Immunity	157
IV. Technique of Transfer Factor Therapy and Prophylaxis of Infection	162
V. Wiskott-Aldrich Syndrome	163
VI. Mucocutaneous Candidiasis	165
VII. Combined Immunodeficiency Disease	166
VIII. Infectious Diseases	167
IX. Diseases of Unknown Etiology	167
X. Malignancy	168
XI. Adverse Reactions	169
XII. Specificity of Transfer	171
XIII. Potential Uses of Transfer Factor	172
XIV. Conclusion	174
References	175

Transfer Factor Therapy in Immunodeficiencies

C. Griscelli

I. Introduction	178
II. Preparation of TF	179
III. Effects in Normal Subjects	181
IV. Effects in Immunodeficiencies	182
V. Effects on Clinical Manifestations	185
VI. Discussion	186
VII. Summary	188
References	189

Immunological Surveillance: Pro and Con

Richmond T. Prehn

I. Historical Introduction	191
II. Tumor Immunogenicity	193
III. Effects of Minimal Immunity on Nascent Tumors	195
IV. Experimental Alteration of the Immune Response	198
V. Experiments of Nature	200
VI. Miscellaneous Correlations	200
VII. Tumor Susceptibility and Phylogeny	201
VIII. General Conclusions	201
References	202

Serology of Cancer

Herbert F. Oettgen

I. Serological Detection of Antigens Associated with Tumors of Experimental Animals	206
II. Serological Approaches to the Study of Viral Oncogenesis	211
III. Serological Detection of Antigens Associated with Human Cancer	218
IV. Conclusions	230
Bibliography	231

The Role of Cell-Mediated Immunity in Control and Growth of Tumors

Karl Erik Hellström and Ingegerd Hellström

I. Introduction	233
II. Evidence That Immune Cells Play an Important Role in the Rejection of Tumors Containing TAA	234

III. Tests for Cell-Mediated Immunity	236
IV. Demonstration of Cell-Mediated Immunity to Animal Tumors	
Using <i>in Vitro</i> Techniques	239
V. Escape Mechanisms from Immunological Surveillance	242
VI. The "Unblocking" Phenomenon	247
VII. "Potentiating" and "Arming" Serum Effects	248
VIII. Cell Types Involved in Host Defense Reactions against Cancer	249
IX. Demonstration of Cell-Mediated Immunity to Human Tumors	250
X. Possible Implications of Tumor Immunology for Cancer Prevention and Therapy	258
XI. Conclusion	263
References	263

Experimental Models of Tumor Immunotherapy

Jon R. Schmidtke and Richard L. Simmons

I. Nonspecific Stimulation of the Immune Apparatus	267
II. Active Specific Immunotherapy	270
III. Adoptive Transfer of Cell-Mediated Immunity	275
IV. Passive Immunotherapy	278
V. Passive Transfer to Immunological Mediators	279
VI. Antiblocking Immunotherapy	280
VII. Discussion	281
References	282

Graft versus Leukemia

Mortimer M. Bortin

I. The Problem	287
II. Conceptual Considerations	288
III. The Treatment Model—Overview	289
IV. The Treatment Model—Dissected	291
V. Recent Experimental Results	301
VI. Clinical Implications?	304
VII. Summary	305
References	306

SUBJECT INDEX	307
---------------	-----

Bone Marrow Transplantation¹

E. DONNALL THOMAS²

Department of Medicine, University of Washington School of Medicine, Seattle, Washington, and the United States Public Health Service Hospital, Seattle, Washington

I. Introduction	2
II. Terminology	4
III. Technique	4
IV. Histocompatibility	5
V. Preparation of the Recipient	7
VI. Clinical Results	8
A. Syngeneic Grafts	8
B. Allogeneic Grafts between HL-A-Matched Donor and Recipient Pairs	9
C. Allogeneic Grafts between HL-A-Mismatched Donor and Recipient Pairs	11
VII. Special Consideration According to Underlying Disease	11
A. Leukemia	11
B. Aplastic Anemia	14
VIII. Support for the Patient without Marrow Function	16
A. Support by Red Blood Cell Transfusions	17
B. Support by Platelet Transfusions	17
C. Support by Granulocyte Transfusions	18
D. The Problem of Sensitization to Transplantation Antigens by Blood Transfusion	19
E. The Problem of GVH Disease from Immunocompetent Cells in Transfused Blood	19
F. Protection against Infection	20

¹ Supported by Research Grants CA 10895, CA 10167 and AI 09419, Contract PH 43-67-1435 and Training Grant CA 05231 from the U.S. Public Health Service, and by Grant CI-52 from the American Cancer Society.

² Recipient of Research Career Award 5 K6 AI 02425 from the U.S. Public Health Service.

IX. Success or Failure of Engraftment	21
X. GVH Disease	21
XI. Immunological Status of Long-term Survivors of Marrow Transplantation	24
XII. Infection following Engraftment	25
XIII. Nature of Tolerance	26
XIV. Antileukemic Effect (Adoptive Immunotherapy)	27
XV. Malignant Transformation of Donor Cells	28
XVI. A Look at the Future	29
References	30

I. Introduction

Modern marrow transplantation began about 1950 with the irradiation protection experiments of Jacobson and of Lorenz and their colleagues. These workers found that mice given otherwise lethal doses of irradiation could be protected from subsequent death due to marrow failure by the administration of spleen or marrow cells. At first it was thought that this protective effect might be due to a humoral factor, but about 1955 several laboratories, using different markers, showed that the protective effect against lethal irradiation was due to the recolonization of the recipient marrow by donor-type cells. These laboratory studies stimulated interest in the clinical application of marrow transplantation for protection in the event of accidental lethal irradiation, or for patients with hematopoietic malignancy who might benefit from high-dose irradiation or chemotherapy given to eradicate their disease. The first article on clinical marrow transplantation appeared in 1957 (Thomas *et al.*, 1957). Despite the promise of these early studies, the next decade was one of frustration and disappointment for would-be marrow transplanters (Thomas and Epstein, 1965; Mathé *et al.*, 1965a). Most of the procedures were carried out in terminally ill patients who did not live long enough for a graft to be evaluated. The few successful allogeneic grafts were followed by an immunological reaction of the engrafted marrow against the host, resulting in a lethal outcome. Recent advances in the knowledge of histocompatibility typing, in the management of graft-versus-host (GVH) disease, and in supportive measures for patients with no marrow function, have renewed interest in the subject of marrow transplantation.

Most of the immunological principles involved in marrow grafting have been defined in inbred mice, and this literature has been reviewed by van Bekkum and de Vries (1967) and by Trentin (1972). Studies